Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Deferred Tax Assets — Valuation Allowance by Year
Deferred Tax Assets — Valuation Allowance ($M) ($M)
Merck Deferred Tax Assets — Valuation Allowance: $824M in FY2025, up 16.1% from a year earlier.
Latest, FY2025
824
Period ended Dec 31, 2025
Change on a year earlier
+16.1%
710 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-K Taxes on Income Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred Tax Assets — Valuation Allowance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 824 | +16.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 710 | +8.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 656 | +9.5% | Form 10-K (filed 2025-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 599 | +108.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 287 | -29.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 404 | -63.3% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 1,100 | -18.4% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 1,348 | +49.8% | Form 10-K (filed 2020-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 900 | +235.8% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 268 | – | Form 10-K (filed 2018-02-27) ↗ |
Cite this data
StockData. (2026). Merck Deferred Tax Assets — Valuation Allowance ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/tax-dta-val
See every metric in the Merck KPI table. Data updated Oct 26, 2026.